Clinical Trial Update: Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating fulvestrant as maintenance therapy after first-line chemotherapy in postmenopausal metastatic breast cancer patients; current status is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)

Snippet

Sponsor: Consorzio Oncotech | Conditions: Metastatic Breast Cancer | Phase 3 | Status: UNKNOWN